Reference
Pruis M, et al. 68P Clinical implications of cardiotoxicity and pharmacokinetics of alectinib in patients (pts) with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Annals of Oncology 33 (Suppl. 2): S63 abstr. 68P, Apr 2022. Available from: URL: http://doi.org/10.1016/j.annonc.2022.02.077 [abstract]
Rights and permissions
About this article
Cite this article
Alectinib. Reactions Weekly 1902, 28 (2022). https://doi.org/10.1007/s40278-022-13172-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-13172-8